Over the last two decades, the utilization of various novel therapies in the upfront or salvage
settings has continued to improve survival outcomes for patients with Multiple Myeloma …

An estimated 22 350 patients had multiple myeloma diagnosed in 2013, representing 1.3%
of all new cancers; 10 710 deaths are projected, representing 1.8% of cancer deaths …

The therapeutic strategy for relapsed and refractory multiple myeloma (RRMM) integrates a
holistic approach regarding patient, disease, and drug-related factors. Patient-related factors …

In spite of significant advances in the management of multiple myeloma (MM), the disease
remains incurable and nearly all patients ultimately relapse and require salvage …

High‐dose chemotherapy and autologous stem cell transplantation (ASCT) are a standard
of care for transplant‐eligible patients with newly diagnosed multiple myeloma (MM). The …

Multiple myeloma (MM), a malignant disorder of plasma cells affecting primarily elderly
patients, is the second most commonly diagnosed hematologic neoplasm. With the recent …

Due to the advent of effective novel therapies for multiple myeloma (MM), the use of
cryopreserved autologous peripheral blood hematopoietic cells (APBHC) for a salvage …

Simple Summary Multiple Myeloma (MM) is the most common cancer of the bone marrow
and remains incurable despite advances in novel therapy. The disease course is typically …

To evaluate the outcomes of salvage third autologous stem cell transplantation (ASCT) in
patients with relapsed multiple myeloma. We analyzed 570 patients who had undergone a …

Background and objectives While the role of autologous stem cell transplant (ASCT) in the
first line therapy for newly diagnosed multiple myeloma is well established, efficacy of ASCT …